Stay updated with breaking news from Michael Soldan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Polpharma Biologics, an international biotech company developing and manufacturing biosimilars, has announced that the European Commission (EC) has approved Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.
Polpharma Biologics, a biotech company developing and manufacturing biosimilars, has announced that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko.
Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple SclerosisAMSTERDAM, The Netherlands, August 25, 2023 / B3C newswire / -- Polpharma Biologics, an international biotech company dedicated to the development and ma...
The FDA is the first regulatory agency globally to approve natalizumab-sztn as a biosimilar for natalizumab.
Therapy is a biosimilar of Lucentis which treats several serious retinal diseases across the European Union - News - PharmaTimes